Novonesis AS 

$62.4
203
-$0.04-0.06% Today

Statistics

Day High
62.56
Day Low
60.38
52W High
75.47
52W Low
52.81
Volume
39,900
Avg. Volume
-
Mkt Cap
0
P/E Ratio
42.47
Dividend Yield
1.63%
Dividend
1.02

Upcoming

Dividends

1.63%Dividend Yield
Apr 26
$0.67
Sep 25
$0.35
Apr 25
$0.61
Sep 24
$0.29
May 24
$0.29
10Y Growth
7.18%
5Y Growth
3.93%
3Y Growth
-10.95%
1Y Growth
5.82%

Earnings

5MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
2.73
4.39
6.05
7.71
Expected EPS
5.161529738631716
Actual EPS
N/A

Financials

7.9%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
4.03BRevenue
318.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NVZMY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap149.77B
Pfizer is a global pharmaceutical company that competes with Novonesis AS in the development and marketing of medications and vaccines for various diseases, including those in areas where Novonesis may operate.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is a leading healthcare company that develops innovative pharmaceuticals and vaccines, directly competing with Novonesis AS in several therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson is a diversified healthcare giant that competes with Novonesis AS through its pharmaceutical division, developing drugs that may overlap with Novonesis' product portfolio.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline is a global healthcare company that competes with Novonesis AS in the pharmaceutical and healthcare market, particularly in the development of vaccines and medications.
Novartis
NVS
Mkt Cap279.67B
Novartis is a multinational pharmaceutical company that competes with Novonesis AS in researching, developing, manufacturing, and marketing a wide range of healthcare products.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie is a biopharmaceutical company that competes with Novonesis AS in the discovery, development, and commercialization of new medicines and therapies.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Novonesis AS in the development of prescription pharmaceuticals in several therapeutic areas.
Roche
RHHBY
Mkt Cap328.49B
Roche Holding AG is a healthcare company that competes with Novonesis AS in the pharmaceutical and diagnostics industries, focusing on oncology, immunology, and infectious diseases.
Sanofi
SNY
Mkt Cap110.4B
Sanofi is a global healthcare leader that competes with Novonesis AS in the development and marketing of therapeutic solutions in areas such as rare diseases, multiple sclerosis, and oncology.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Novonesis AS in the discovery, development, and commercialization of prescription medicines, particularly in the oncology sector.

About

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Show more...
CEO
Ms. Ester Baiget
Employees
10582
Country
United States
ISIN
US6701081092

Listings

0 Comments

Share your thoughts

FAQ

What is Novonesis AS stock price today?
The current price of NVZMY is $62.4 USD — it has decreased by -0.06% in the past 24 hours. Watch Novonesis AS stock price performance more closely on the chart.
What is Novonesis AS stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Novonesis AS stocks are traded under the ticker NVZMY.
Is Novonesis AS stock price growing?
NVZMY stock has risen by +4.26% compared to the previous week, the month change is a +3.79% rise, over the last year Novonesis AS has showed a -4.28% decrease.
When is the next Novonesis AS earnings date?
Novonesis AS is going to release the next earnings report on August 20, 2026.
What is Novonesis AS revenue for the last year?
Novonesis AS revenue for the last year amounts to 4.03B USD.
What is Novonesis AS net income for the last year?
NVZMY net income for the last year is 318.85M USD.
Does Novonesis AS pay dividends?
Yes, NVZMY dividends are paid semi-annual. The last dividend per share was 0.67 USD. As of today, Dividend Yield (FWD)% is 1.63%.
How many employees does Novonesis AS have?
As of May 06, 2026, the company has 10,582 employees.
In which sector is Novonesis AS located?
Novonesis AS operates in the Materials sector.
When did Novonesis AS complete a stock split?
Novonesis AS has not had any recent stock splits.
Where is Novonesis AS headquartered?
Novonesis AS is headquartered in Lyngby, United States.